Close Menu

NEW YORK – Natera has priced a follow-on offering of its common stock at $35 per share, the San Carlos, California-based molecular diagnostics firm announced this morning.

Natera is offering 5,714,286 shares of its common stock, which would result in gross proceeds of $200 million. If the underwriters exercise their option to an additional 857,142 shares of Natera's common stock, that would bring in an additional $30 million in gross proceeds.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.